UY39327A - Anticuerpos anti- alpha-4-beta-7 - Google Patents

Anticuerpos anti- alpha-4-beta-7

Info

Publication number
UY39327A
UY39327A UY0001039327A UY39327A UY39327A UY 39327 A UY39327 A UY 39327A UY 0001039327 A UY0001039327 A UY 0001039327A UY 39327 A UY39327 A UY 39327A UY 39327 A UY39327 A UY 39327A
Authority
UY
Uruguay
Prior art keywords
beta
alpha
antibodies
bind
manufacture
Prior art date
Application number
UY0001039327A
Other languages
English (en)
Inventor
Feng Dong
Jing Min
Teresa, (Lok-Chan) Ng
Jacqueline Bixby
Tatyana Dekhtyar
Axel Hernandez
Preethi Krishnan
Liangjun Lu
Federico Mensa
Gautam Sahu
Renee Miller
Lorenzo Benatuil
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of UY39327A publication Critical patent/UY39327A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente descripción proporciona anticuerpos anti-alpha-4-beta-7 que se unen a anti-alpha-4-beta-7 humanas, sus métodos de fabricación y sus usos para tratar pacientes con infección por VIH.
UY0001039327A 2020-07-16 2021-07-15 Anticuerpos anti- alpha-4-beta-7 UY39327A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063052933P 2020-07-16 2020-07-16

Publications (1)

Publication Number Publication Date
UY39327A true UY39327A (es) 2022-02-25

Family

ID=77338969

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039327A UY39327A (es) 2020-07-16 2021-07-15 Anticuerpos anti- alpha-4-beta-7

Country Status (16)

Country Link
US (1) US11639390B2 (es)
EP (1) EP4182349A1 (es)
JP (2) JP7408008B2 (es)
KR (1) KR20230038728A (es)
CN (1) CN115867352A (es)
AR (1) AR122983A1 (es)
AU (1) AU2021307468A1 (es)
BR (1) BR112023000718A2 (es)
CA (1) CA3188739A1 (es)
CO (1) CO2023001066A2 (es)
IL (1) IL299767A (es)
MX (1) MX2023000732A (es)
TW (1) TW202216781A (es)
UY (1) UY39327A (es)
WO (1) WO2022016198A1 (es)
ZA (1) ZA202300222B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2301254T3 (es) 1998-11-18 2008-06-16 Genentech, Inc. Variantes de anticuerpos con una afinidad de union mayor en comparacion con los anticuerpos parentales.
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
AP2015008338A0 (en) 2012-09-26 2015-04-30 Kflp Biotech Llc Compounds for the treatment and prevention of retroviral infections
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life

Also Published As

Publication number Publication date
JP7408008B2 (ja) 2024-01-04
BR112023000718A2 (pt) 2023-02-07
JP2023535556A (ja) 2023-08-18
CO2023001066A2 (es) 2023-02-06
US11639390B2 (en) 2023-05-02
MX2023000732A (es) 2023-02-13
CN115867352A (zh) 2023-03-28
JP2024037932A (ja) 2024-03-19
AU2021307468A1 (en) 2023-02-02
EP4182349A1 (en) 2023-05-24
AR122983A1 (es) 2022-10-19
CA3188739A1 (en) 2022-01-20
TW202216781A (zh) 2022-05-01
ZA202300222B (en) 2023-09-27
IL299767A (en) 2023-03-01
WO2022016198A1 (en) 2022-01-20
US20220017624A1 (en) 2022-01-20
KR20230038728A (ko) 2023-03-21

Similar Documents

Publication Publication Date Title
CO2018003738A2 (es) Anticuerpos anti-lag3 y sus usos
DOP2022000166A (es) Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos
CL2018002694A1 (es) Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112)
BR112018067525A2 (pt) anticorpos tendo especificidade para o btla e seus usos
CL2020003223A1 (es) Anticuerpos il-11
CO2017005240A2 (es) Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción
CL2021002994A1 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. (divisional de la solicitud no. 201900067)
CL2020003026A1 (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
CO2017002719A2 (es) Anticuerpos anti-glucagón
CO2020012415A2 (es) Anticuerpos de unión a vista a ph ácido
DOP2020000236A (es) Anticuerpos il-1 1ra
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
PE20210488A1 (es) Anticuerpos especificos para gucy2c y sus usos
CL2018000750A1 (es) Método de redireccionamiento de linfocitos t para el tratamiento de la infección por vih
CL2020002446A1 (es) Anticuerpos contra mica y/o micb y sus usos
ECSP20029142A (es) Ligandos de psma para la formación de imágenes y endorradioterapia
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CL2017000212A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
CO2021000046A2 (es) Anticuerpos de unión a vista a ph ácido
AR115288A1 (es) Anticuerpos humanizados contra el psma
UY39327A (es) Anticuerpos anti- alpha-4-beta-7
BR112021010634A2 (pt) Anticorpos antiperiostina e usos dos mesmos
DOP2023000039A (es) Moléculas de unión a antígeno multi-específicas contra el vih y métodos de uso
BR112017005134A2 (pt) tratamento e cura funcional de infecção por hiv por anticorpos monoclonais para inibição de entrada de hiv competitiva mediada por cd